COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee
2021
Turner, Paul | Ansotegui, Ignacio J. | Campbell, Dianne E. | Cardona, Victoria | Ebisawa, Motohiro | El-Gamal, Yehia | Fineman, Stanley | Geller, Mario | Gonzalez-Estrada, Alexei | Greenberger, Paul A. | Leung, Agnes S.Y. | Levin, Michael E. | Muraro, Antonella | Sánchez Borges, Mario | Senna, Gianenrico | Tanno, L.K. | Thong, Bernard Yu-Hor | Worm, Margitta | National Heart and Lung Institute [London] (NHLI) ; Imperial College London-Royal Brompton and Harefield NHS Foundation Trust | The University of Sydney | Hospital Quirónsalud Bizkaia [Bilbao] | DataLab Group [Montrouge] | Vall d'Hebron University Hospital [Barcelona] | Sagamihara National Hospital [Kanagawa, Japan] | Ain Shams University (ASU) | Emory University School of Medicine ; Emory University [Atlanta, GA] | Academia Nacional de Medicina | Mayo Clinic [Jacksonville] | Feinberg School of Medicine [Northwestern University, Evanston] ([Northwestern University Medical School]) ; Northwestern University [Evanston] | Prince of Wales Hospital | University of Cape Town | Food Allergy Referral Centre Veneto Region [Padua, Italy] ; Università degli Studi di Padova = University of Padua (Unipd) | Centro Médico Docente La Trinidad | Università degli studi di Verona = University of Verona (UNIVR) | Hospital Sírio-Libanês [São Paulo, Brazil] | Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier) | Centre for Research in Epidemiology and Statistics | Centre de Recherche Épidémiologie et Statistiques (CRESS (U1153 / UMR_A 1125)) ; Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE) | Tan Tock Seng Hospital | Charité - UniversitätsMedizin = Berlin University Medicine
International audience
Mostrar más [+] Menos [-]Inglés. Vaccines against COVID-19 (and its emerging variants) are an essential global intervention to control the current pandemic situation. Vaccines often cause adverse events; however, the vast majority of adverse events following immunization (AEFI) are a consequence of the vaccine stimulating a protective immune response, and not allergic in etiology. Anaphylaxis as an AEFI is uncommon, occurring at a rate of less than 1 per million doses for most vaccines. However, within the first days of initiating mass vaccination with the Pfizer-BioNTech COVID-19 vaccine BNT162b2, there were reports of anaphylaxis from the United Kingdom and United States. More recent data imply an incidence of anaphylaxis closer to 1:200,000 doses with respect to the Pfizer-BioNTech vaccine. In this position paper, we discuss the background to reactions to the current COVID-19 vaccines and relevant steps to mitigate against the risk of anaphylaxis as an AEFI. We propose a global surveillance strategy led by allergists in order to understand the potential risk and generate data to inform evidence-based guidance, and thus provide reassurance to public health bodies and members of the public.
Mostrar más [+] Menos [-]Palabras clave de AGROVOC
Información bibliográfica
Este registro bibliográfico ha sido proporcionado por Institut national de la recherche agronomique
